최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한방사선종양학회지 = The Journal of the Korean soceity for therapeutic radiology and oncology, v.25 no.2, 2007년, pp.70 - 78
유정일 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) , 오동렬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) , 허승재 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) , 최한용 (성균관대학교 의과대학 삼성서울병원 비뇨기과) , 이현무 (성균관대학교 의과대학 삼성서울병원 비뇨기과) , 전성수 (성균관대학교 의과대학 삼성서울병원 비뇨기과) , 임호영 (성균관대학교 의과대학 삼성서울병원 혈액종양내과) , 김원석 (성균관대학교 의과대학 삼성서울병원 혈액종양내과) , 임도훈 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) , 안용찬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) , 박원 (성균관대학교 의과대학 삼성서울병원 방사선종양학과)
[
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Cheon J, Kim CS, Lee ES, et al. Survey of incidence of urological cancer in South Korea: a 15-year summary. lnt J Urol 2002;9:445-454
Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 1995; 154:2059-2063
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675
Birkenhake S, Martus p, Kuhn R, Schroll KM, Sauer R. Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer. Strahlenther Onkol 1998;174:121-127
Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-499
Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Allar lA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997; 158:393- 399
Lehmann J, Retz M, Stockle M. The role of adjuvant chemotherapy for muscle invasive bladder cancer. World J Urol 2001;19:133-140.
Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16:3576-3583
Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995; 153:47-52
Shipley WU, Rose MA. Bladder cancer. The selection of patients for treatment by full-dose irradiation. Cancer 198555: 2278-2284
Sauer R, Birkenhake S, Kuhn R, Willekind C, Schroll KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. lnt J Radiat Oncol Biol Phys 1998;40:121-127
Birkenhake S, Leykamm S, Martus P, Sauer R. Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results. Strahlenther Onkol 1999;175:97-101
Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1448-1453
Rodel C, Grabenbauer GG, Kuhn R, et al. Combinedmodality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-3071
Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001;166:19-23
Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449-454
Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165: 1111-1116
Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 2003;43:246-257
McDougal WS. Metabolic complications of urinary intestinal diversion. J Urol 1992;147:1199-1208
Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol 2000; 164:627-632
Quilty PM, Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. lnt J Radiat Oncol Biol Phys 1986;12:853-860
Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 2003;97:2115-2119
Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170: 1772-1776
Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119-126
Moonen L, vd Voet H, de Nijs R, Hart AA, Horenblas S, Bartelink H. Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment. Radiother Oncol 1998;49: 149-155
Morrison R. The results of treatment of cancer of the bladder - a clinical contribution to radiobiology. Clin Radiol 1975;26: 67-75
Chung WK, Oh BR, Ahn SJ. The prognostic factors affecting survival in muscle invasive bladder cancer treated with radiotherapy. J Korean Soc Ther Radiol Oncol 2002;20:130-138
Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7:299-310
Hayter CR, Paszat LF, Groome PA, Schulze K, Math M, Mackillop WJ. A population-based study of the use and outcome of radical radiotherapy for invasive bladder cancer. lnt J Radiat Oncol Biol Phys 1999;45:1239-1245
Cho JH, Lim JH, Seong JS. Bladder preservation by combined modality therapy for invasive bladder cancer: a five-year follow-up. J Korean Soc Ther Radiol Oncol 2001;19:359-368
Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. lnt J Radiat Oncol Biol Phys 1995;31 :247-254
Yoon SM, Yang KM, Lee HS. Combined modality therapy with selective bladder preservation for muscle invading bladder cancer. J Korean Soc Ther Radiol Oncol 2001;19:237-244
Shipley WU, Prout GR Jr, Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. Jama 1987;258:931-935
Jacobsen AB, Lunde S, Ous S, et al. T2/T3 bladder carcinomas treated with definitive radiotherapy with emphasis on flow cytometric DNA ploidy values. lnt J Radiat Oncol Biol Phys 1989; 17:923-929
※ AI-Helper는 부적절한 답변을 할 수 있습니다.